Relation of circulating concentrations of chemokine receptor CCR5 ligands to C-peptide, proinsulin and HbA1c and disease progression in type 1 diabetes

Clinical Immunology

Volumn 128, Issue 1, 2008, Pages 57-65

  Pfleger, C ^a   Kaas, A ^b   Hansen, L ^c   Alizadeh, B ^d   Hougaard, P ^e   Holl, R ^f   Kolb, H ^a   Roep, B O ^g   Mortensen, H B ^b   Schloot, N C ^a,h  

^a LEIBNIZ CENTER FOR DIABETES RESEARCH AT HEINRICH HEINE UNIVERSITY DÜSSELDORF   (Germany)

^b GLOSTRUP UNIVERSITY HOSPITAL   (Denmark)

^c NOVO NORDISK A S   (Denmark)

^d ERASMUS MEDICAL CENTER   (Netherlands)

^e UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

^f UNIVERSITY OF ULM   (Germany)

^g LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^h HEINRICH HEINE UNIVERSITY   (Germany)

Author keywords

C peptide; CCL3 MIP 1alpha; CCL4 MIP 1beta; CCL5 RANTES; Children; Disease progression; Inflammation; Proinsulin; Remission; Type 1 diabetes mellitus

Indexed keywords

BIOLOGICAL MARKER; C PEPTIDE; CHEMOKINE RECEPTOR CCR5; HEMOGLOBIN A1C; LIGAND; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MARAVIROC; PROINSULIN; RANTES;

ADOLESCENT; ARTICLE; CELL STRESS; CHILD; DIABETIC PATIENT; DISEASE COURSE; FEMALE; HUMAN; INFANT; INSULIN DEPENDENT DIABETES MELLITUS; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; PANCREAS ISLET BETA CELL; PRIORITY JOURNAL; REMISSION; TH1 CELL; TH2 CELL;

ADOLESCENT; BIOLOGICAL MARKERS; C-PEPTIDE; CHEMOKINE CCL3; CHEMOKINE CCL4; CHEMOKINE CCL5; CHEMOKINES; CHILD; CHILD, PRESCHOOL; DIABETES MELLITUS, TYPE 1; DISEASE PROGRESSION; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; INFANT; MALE; PROINSULIN; RECEPTORS, CCR5;

EID: 49949152528     PISSN: 15216616     EISSN: 15217035     Source Type: Journal    
DOI: 10.1016/j.clim.2008.03.458     Document Type: Article

References (34)

1. Atkinson M.A., and Eisenbarth G.S. Type 1 diabetes: new perspectives on disease pathogenesis and treatment. Lancet 358 (2001) 221-229
2. Luster A.D. Chemokines-chemotactic cytokines that mediate inflammation. N. Engl. J. Med. 338 (1998) 436-445
3. Bradley L.M., Asensio V.C., Schioetz L.K., Harbertson J., Krahl T., Patstone G., Woolf N., Campbell I.L., and Sarvetnick N. Islet-specific Th1, but not Th2, cells secrete multiple chemokines and promote rapid induction of autoimmune diabetes. J. Immunol. 162 (1999) 2511-2520
4. Carvalho-Pinto C., Garcia M.I., Gomez L., Ballesteros A., Zaballos A., Flores J.M., Mellado M., Rodriguez-Frade J.M., Balomenos D., and Martinez A. Leukocyte attraction through the CCR5 receptor controls progress from insulitis to diabetes in non-obese diabetic mice. Eur. J. Immunol. 34 (2004) 548-557
5. Abdi R., Smith R.N., Makhlouf L., Najafian N., Luster A.D., Auchincloss Jr. H., and Sayegh M.H. The role of CC chemokine receptor 5 (CCR5) in islet allograft rejection. Diabetes 51 (2002) 2489-2495
6. Cnop M., Welsh N., Jonas J.C., Jorns A., Lenzen S., and Eizirik D.L. Mechanisms of pancreatic beta-cell death in type 1 and type 2 diabetes: many differences, few similarities. Diabetes 54 Suppl 2 (2005) S97-S107
7. Ramnath R.D., and Bhatia M. Substance P treatment stimulates chemokine synthesis in pancreatic acinar cells via the activation of NF-kappaB. Am. J. Physiol. Gastrointest. Liver Physiol. 291 (2006) G1113-G1119
8. Yang B.M., Demaine A.G., and Kingsnorth A. Chemokines MCP-1 and RANTES in isolated rat pancreatic acinar cells treated with CCK and ethanol in vitro. Pancreas 21 (2000) 22-31
9. Hanifi-Moghaddam P., Kappler S., Seissler J., Muller-Scholze S., Martin S., Roep B.O., Strassburger K., Kolb H., and Schloot N.C. Altered chemokine levels in individuals at risk of Type 1 diabetes mellitus. Diabet. Med. 23 (2006) 156-163
10. Lohmann T., Laue S., Nietzschmann U., Kapellen T.M., Lehmann I., Schroeder S., Paschke R., and Kiess W. Reduced expression of Th1-associated chemokine receptors on peripheral blood lymphocytes at diagnosis of type 1 diabetes. Diabetes 51 (2002) 2474-2480
11. Mortensen H.B., and Hougaard P. Comparison of metabolic control in a cross-sectional study of 2,873 children and adolescents with IDDM from 18 countries. The Hvidore Study Group on Childhood Diabetes. Diabetes Care 20 (1997) 714-720
12. Nielsen L.B., Mortensen H.B., Chiarelli F., Holl R., Swift P., de Beaufort C., Pociot F., Hougaard P., Gammeltoft S., Knip M., and Hansen L. Impact of IDDM2 on disease pathogenesis and progression in children with newly diagnosed type 1 diabetes: reduced insulin antibody titres and preserved beta cell function. Diabetologia 49 (2006) 71-74
13. Alberti K.G., and Zimmet P.Z. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet. Med. 15 (1998) 539-553
14. Effects of age, duration and treatment of insulin-dependent diabetes mellitus on residual beta-cell function: observations during eligibility testing for the Diabetes Control and Complications Trial (DCCT). The DCCT Research Group. J. Clin. Endocrinol. Metab. 65 (1987) 30-36
15. Effect of intensive therapy on residual beta-cell function in patients with type 1 diabetes in the diabetes control and complications trial. A randomized, controlled trial. The Diabetes Control and Complications Trial Research Group. Ann. Intern. Med. 128 (1998) 517-523
16. de Beaufort C.E., Swift P.G., Skinner C.T., Aanstoot H.J., Aman J., Cameron F., Martul P., Chiarelli F., Daneman D., Danne T., Dorchy H., Hoey H., Kaprio E.A., Kaufman F., Kocova M., Mortensen H.B., Njolstad P.R., Phillip M., Robertson K.J., Schoenle E.J., Urakami T., and Vanelli M. Continuing stability of center differences in pediatric diabetes care: do advances in diabetes treatment improve outcome? The Hvidoere Study Group on Childhood Diabetes. Diabetes Care 30 (2007) 2245-2250
17. Schloot N.C., Hanifi-Moghaddam P., Aabenhus-Andersen N., Alizadeh B.Z., Saha M.T., Knip M., Devendra D., Wilkin T., Bonifacio E., Roep B.O., Kolb H., and Mandrup-Poulsen T. Association of immune mediators at diagnosis of Type 1 diabetes with later clinical remission. Diabet. Med. 24 (2007) 512-520
18. Kempf K., Rose B., Herder C., Kleophas U., Martin S., and Kolb H. Inflammation in metabolic syndrome and type 2 diabetes: Impact of dietary glucose. Ann. N. Y. Acad. Sci. 1084 (2006) 30-48
19. Herder C., Haastert B., Muller-Scholze S., Koenig W., Thorand B., Holle R., Wichmann H.E., Scherbaum W.A., Martin S., and Kolb H. Association of systemic chemokine concentrations with impaired glucose tolerance and type 2 diabetes: results from the Cooperative Health Research in the Region of Augsburg Survey S4 (KORA S4). Diabetes 54 Suppl 2 (2005) S11-S17
20. Variation and trends in incidence of childhood diabetes in Europe. EURODIAB ACE Study Group. Lancet 355 (2000) 873-876
21. Todd J.A., Walker N.M., Cooper J.D., Smyth D.J., Downes K., Plagnol V., Bailey R., Nejentsev S., Field S.F., Payne F., Lowe C.E., Szeszko J.S., Hafler J.P., Zeitels L., Yang J.H., Vella A., Nutland S., Stevens H.E., Schuilenburg H., Coleman G., Maisuria M., Meadows W., Smink L.J., Healy B., Burren O.S., Lam A.A., Ovington N.R., Allen J., Adlem E., Leung H.T., Wallace C., Howson J.M., Guja C., Ionescu-Tirgoviste C., Simmonds M.J., Heward J.M., Gough S.C., Dunger D.B., Wicker L.S., and Clayton D.G. Robust associations of four new chromosome regions from genome-wide analyses of type 1 diabetes. Nat. Genet. 39 (2007) 857-864
22. Mortensen H.B., Robertson K.J., Aanstoot H.J., Danne T., Holl R.W., Hougaard P., Atchison J.A., Chiarelli F., Daneman D., Dinesen B., Dorchy H., Garandeau P., Greene S., Hoey H., Kaprio E.A., Kocova M., Martul P., Matsuura N., Schoenle E.J., Sovik O., Swift P.G., Tsou R.M., Vanelli M., and Aman J. Insulin management and metabolic control of type 1 diabetes mellitus in childhood and adolescence in 18 countries. Hvidore Study Group on Childhood Diabetes. Diabet. Med. 15 (1998) 752-759
23. Cameron M.J., Arreaza G.A., Grattan M., Meagher C., Sharif S., Burdick M.D., Strieter R.M., Cook D.N., and Delovitch T.L. Differential expression of CC chemokines and the CCR5 receptor in the pancreas is associated with progression to type I diabetes. J. Immunol. 165 (2000) 1102-1110
24. Meagher C., Arreaza G., Peters A., Strathdee C.A., Gilbert P.A., Mi Q.S., Santamaria P., Dekaban G.A., and Delovitch T.L. CCL4 protects from type 1 diabetes by altering islet beta-cell-targeted inflammatory responses. Diabetes 56 (2007) 809-817
25. Schall T.J., Bacon K., Camp R.D., Kaspari J.W., and Goeddel D.V. Human macrophage inflammatory protein alpha (MIP-1 alpha) and MIP-1 beta chemokines attract distinct populations of lymphocytes. J. Exp. Med. 177 (1993) 1821-1826
26. Chen W., Salojin K.V., Mi Q.S., Grattan M., Meagher T.C., Zucker P., and Delovitch T.L. Insulin-like growth factor (IGF)-I/IGF-binding protein-3 complex: therapeutic efficacy and mechanism of protection against type 1 diabetes. Endocrinology 145 (2004) 627-638
27. Zhernakova A., Alizadeh B.Z., Eerligh P., Hanifi-Moghaddam P., Schloot N.C., Diosdado B., Wijmenga C., Roep B.O., and Koeleman B.P. Genetic variants of RANTES are associated with serum RANTES level and protection for type 1 diabetes. Genes Immun. 7 (2006) 544-549
28. Hartling S.G., Lindgren F., Dahlqvist G., Persson B., and Binder C. Elevated proinsulin in healthy siblings of IDDM patients independent of HLA identity. Diabetes 38 (1989) 1271-1274
29. Pfutzner A., Kunt T., Hohberg C., Mondok A., Pahler S., Konrad T., Lubben G., and Forst T. Fasting intact proinsulin is a highly specific predictor of insulin resistance in type 2 diabetes. Diabetes Care 27 (2004) 682-687
30. Snorgaard O., Hartling S.G., and Binder C. Proinsulin and C-peptide at onset and during 12 months cyclosporin treatment of type 1 (insulin-dependent) diabetes mellitus. Diabetologia 33 (1990) 36-42
31. Yki-Jarvinen H., and Koivisto V.A. Natural course of insulin resistance in type I diabetes. N. Engl. J. Med. 315 (1986) 224-230
32. Lombardo F., Valenzise M., Wasniewska M., Messina M.F., Ruggeri C., Arrigo T., and De Luca F. Two-year prospective evaluation of the factors affecting honeymoon frequency and duration in children with insulin dependent diabetes mellitus: the key-role of age at diagnosis. Diabetes Nutr. Metab. 15 (2002) 246-251
33. Jahromi M.M., and Eisenbarth G.S. Genetic determinants of type 1 diabetes across populations. Ann. N.Y. Acad. Sci. 1079 (2006) 289-299
34. Pickering R.M., and Weatherall M. The analysis of continuous outcomes in multi-centre trials with small centre sizes. Stat. Med. 26 (2007) 5445-5456